Becker muscular dystrophy severity is linked to the structure of dystrophin.
暂无分享,去创建一个
V. Vié | M. Claustres | F. Leturcq | O. Delalande | E. Le Rumeur | A. Nicolas | J. Hubert | A. Chéron | S. Tuffery-Giraud | E. Giudice | C. Raguenes-Nicol | R. Ben Yaou | Sarah Ameziane-Le Hir | Aurélie Nicolas
[1] E. Blaurock-Busch. EDTA: Ethylene Diamine Tetra Acetic Acid – A Review , 2016 .
[2] K. Flanigan,et al. Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? , 2014, Neuromuscular Disorders.
[3] O. Delalande,et al. The spectrin family of proteins: a unique coiled-coil fold for various molecular surface properties. , 2014, Journal of structural biology.
[4] Nathalie Jette,et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.
[5] Y. Takeshima,et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy , 2014, Journal of Human Genetics.
[6] V. Vié,et al. Cholesterol favors the anchorage of human dystrophin repeats 16 to 21 in membrane at physiological surface pressure. , 2014, Biochimica et biophysica acta.
[7] L. Popplewell,et al. New developments in the use of gene therapy to treat Duchenne muscular dystrophy , 2014, Expert opinion on biological therapy.
[8] H. Kan,et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[9] Eric P Hoffman,et al. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. , 2013, Discovery medicine.
[10] Domenica Taruscio,et al. The TREAT‐NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia , 2013, Human mutation.
[11] O. Delalande,et al. Molecular clues about the dystrophin-neuronal nitric oxide synthase interaction: a theoretical approach. , 2013, Biochemistry.
[12] J. Verschuuren,et al. Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[13] K. Davies,et al. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.
[14] F. Leturcq,et al. Variable phenotype of del45-55 Becker patients correlated with nNOSμ mislocalization and RYR1 hypernitrosylation. , 2012, Human molecular genetics.
[15] M. Muthu,et al. The Crystal Structures of Dystrophin and Utrophin Spectrin Repeats: Implications for Domain Boundaries , 2012, PloS one.
[16] G. Comi,et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy , 2012, Neurology.
[17] P. Soler-Palacín,et al. Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion , 2012, Orphanet Journal of Rare Diseases.
[18] L. Popplewell,et al. Genetic therapeutic approaches for Duchenne muscular dystrophy. , 2012, Human gene therapy.
[19] K. Bushby,et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.
[20] J. Vissing,et al. Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[21] G. Lanfranchi,et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy , 2011, Neurology.
[22] O. Delalande,et al. Computational Study of the Human Dystrophin Repeats: Interaction Properties and Molecular Dynamics , 2011, PloS one.
[23] J. Ervasti,et al. Internal deletion compromises the stability of dystrophin. , 2011, Human molecular genetics.
[24] Anna Carla Turconi,et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up , 2011, Journal of Neurology.
[25] D. Cacchiarelli,et al. miR‐31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy , 2011, EMBO reports.
[26] S. Winder,et al. Dystrophin: more than just the sum of its parts. , 2010, Biochimica et biophysica acta.
[27] Annemieke Aartsma-Rus,et al. Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy , 2010, RNA biology.
[28] J. T. Dunnen,et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients , 2010, Neuromuscular Disorders.
[29] Livija Medne,et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.
[30] A. Pestronk,et al. Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy , 2009, Circulation. Cardiovascular genetics.
[31] S. Hardy,et al. Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. , 2009, Journal of molecular biology.
[32] Christophe Béroud,et al. Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.
[33] Roman G. Efremov,et al. PLATINUM: a web tool for analysis of hydrophobic/hydrophilic organization of biomolecular complexes , 2009, Bioinform..
[34] S. Hardy,et al. A Two-amino Acid Mutation Encountered in Duchenne Muscular Dystrophy Decreases Stability of the Rod Domain 23 (R23) Spectrin-like Repeat of Dystrophin* , 2009, Journal of Biological Chemistry.
[35] D. Duan,et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.
[36] J. Chamberlain,et al. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. , 2008, Human molecular genetics.
[37] J. Finsterer,et al. Cardiac involvement in Becker muscular dystrophy. , 2008, The Canadian journal of cardiology.
[38] S. Hardy,et al. Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties. , 2008, Biochimica et biophysica acta.
[39] F. Muntoni,et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human , 2007, Neuromuscular Disorders.
[40] T. Partridge,et al. Optimizing exon skipping therapies for DMD. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[41] James M. Allen,et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[42] J. Ervasti. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. , 2007, Biochimica et biophysica acta.
[43] M. Schwartz,et al. Deletion of exon 16 of the dystrophin gene is not associated with disease , 2007, Human mutation.
[44] Christophe Béroud,et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.
[45] Edgar Jacoby,et al. Molecular lipophilicity in protein modeling and drug design. , 2007, Current medicinal chemistry.
[46] G. van Ommen,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.
[47] N. Menhart. Hybrid spectrin type repeats produced by exon-skipping in dystrophin. , 2006, Biochimica et biophysica acta.
[48] Simon C Watkins,et al. Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells , 2006, Journal of Muscle Research & Cell Motility.
[49] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[50] F. Salvatore,et al. Analysis of Dystrophin Gene Deletions Indicates that the Hinge III Region of the Protein Correlates with Disease Severity , 2005 .
[51] Alexander D. MacKerell,et al. Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..
[52] G. Dickson,et al. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins , 2004, Gene Therapy.
[53] Dongsheng Duan,et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.
[54] Nathan A. Baker,et al. Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[55] T. Braun,et al. Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy , 2000, Neuromuscular Disorders.
[56] Alexander D. MacKerell,et al. All‐atom empirical force field for nucleic acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data , 2000 .
[57] Alexander D. MacKerell,et al. All‐atom empirical force field for nucleic acids: II. Application to molecular dynamics simulations of DNA and RNA in solution , 2000 .
[58] D. Davis,et al. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. , 2000, Human molecular genetics.
[59] L. Anderson,et al. Multiplex Western blotting system for the analysis of muscular dystrophy proteins. , 1999, The American journal of pathology.
[60] J. Ervasti,et al. A Cluster of Basic Repeats in the Dystrophin Rod Domain Binds F-actin through an Electrostatic Interaction* , 1998, The Journal of Biological Chemistry.
[61] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[62] L. Morandi,et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype , 1995, Journal of the Neurological Sciences.
[63] T. Gibson,et al. Dystrophin and utrophin: the missing links! , 1995, FEBS letters.
[64] E. Kahana,et al. Minimum folding unit of dystrophin rod domain. , 1995, Biochemistry.
[65] N. Bresolin,et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. , 1994, Brain : a journal of neurology.
[66] M. Sippl. Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.
[67] H. Sweeney,et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[69] K. Bushby,et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy , 1993, Journal of Neurology.
[70] H Sugita,et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.
[71] M. Thambyayah,et al. Prevalence and incidence of Becker muscular dystrophy , 1991, The Lancet.
[72] K. Davies,et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.
[73] L. Kunkel,et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.
[74] A. Monaco,et al. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.
[75] M. Koenig,et al. Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.
[76] Annemieke Aartsma-Rus. Dystrophin Analysis in Clinical Trials. , 2014, Journal of neuromuscular diseases.
[77] Bernard Dan,et al. Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.
[78] Tae-Jin Song,et al. Cardiac Assessment in Duchenne and Becker Muscular Dystrophies , 2007 .
[79] J. Felsenstein. Estimation of hominoid phylogeny from a DNA hybridization data set , 2005, Journal of Molecular Evolution.